The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro.
Drogan
Daniel
D
University of Erlangen-Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany.
Rauch
Pia
P
Hoffmann
Daniel
D
Walter
Hauke
H
Metzner
Karin J
KJ
D000483:Alleles; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002460:Cell Line; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D012367:RNA, Viral / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000821:virology; D019562:Viral Load
D019380:Anti-HIV Agents; D012367:RNA, Viral; D003841:Deoxycytidine; D019259:Lamivudine; D000068679:Emtricitabine